Nivolumab Plus Stereotactic Body Radiotherapy in II and III Line of Patients With Metastatic Renal Cell Carcinoma

NCT03469713 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

69

Enrollment

OTHER

Sponsor class

Conditions

Renal Cancer Metastatic

Interventions

DRUG: Nivolumab

Sponsor

Gruppo Oncologico Italiano di Ricerca Clinica